NUVESSA and CLINDESSE are branded vaginal treatments for bacterial vaginosis that use a single administration. Nuvessa is metronidazole 1.3% gel; Clindesse is clindamycin phosphate 2% vaginal cream in a prefilled applicator. The coincidence of a one-time regimen should not obscure a difference in active ingredient, vehicle, contraindications and patient counseling. Both products require an appropriate BV diagnosis and a prescription.
This page compares two specific brand presentations, not the entire class of metronidazole vaginal gels or clindamycin creams. In particular, the commonly prescribed multi-day metronidazole 0.75% gel and multi-day 2% clindamycin cream have their own labeled uses and are better assessed through the standard gel-versus-cream comparison.
The practical pharmacy task is to match the brand, percentage, route, single-dose package and counseling instructions to the authorized medicine. For additional product context, review Nuvessa 1.3% or Clindesse prescription purchasing considerations. Neither a pharmacy’s stock position nor a checkout preference can replace the prescriber’s choice of active antibiotic.
This comparison starts with the product, route and indication rather than a promise that one medicine is faster, stronger or cheaper. The differences in the matrix help a patient identify exactly what a clinician has prescribed for Nuvessa vs Clindesse. They are not a self-treatment chart, and the actual product label should control administration.
One single-dose applicator of gel and one single-dose applicator of cream can appear similar at checkout but differ meaningfully after dispensing. Clindesse has mineral-oil-containing cream and associated latex/rubber barrier counseling, whereas Nuvessa has a distinct metronidazole gel label. Comparing package count alone would conceal both the different antibiotic and the different vehicle.
| Comparison point | NUVESSA | CLINDESSE |
|---|---|---|
| Feature | NUVESSA | CLINDESSE |
| Active drug | Metronidazole | Clindamycin phosphate |
| Form | 1.3% vaginal gel | 2% vaginal cream |
| Package design | Single prefilled applicator | Single prefilled applicator |
| Course | One vaginal administration | One vaginal administration |
| Vehicle consideration | Gel and its own excipients | Cream containing mineral oil |
| Barrier warning | Follow Nuvessa label | Mineral oil: avoid latex/rubber barriers during and for 5 days after treatment |
| Population and prescribing label | BV in females aged 12 years and older | BV in non-pregnant women; discuss patient-specific circumstances |
| Can swap by same dose count? | No | No |
A single applicator may suggest similar convenience, but it does not establish identical exposure to the active drug, comparable effectiveness in each individual or matching safety constraints. The antibiotics belong to different classes. The prescribed brand and strength reflect a clinical choice, not a general category called single-dose BV medicine.
A pharmacy should not replace Nuvessa with Clindesse as a generic substitution. A clinician needs to consider whether a different antimicrobial is suitable. This distinction remains even if an insurer pays for one more readily than the other.
Nuvessa is a vaginal gel, while Clindesse is a vaginal cream with its own excipients and applicator. A person who experiences irritation or has particular administration difficulties should explain those concerns to a clinician, who may consider the vehicle when making a prescription decision.
The correct administration is the one provided with the dispensed package. Do not refill a disposable applicator, copy the timing of an older vaginal course or assume that a previous 0.75% metronidazole gel order can be treated as equivalent to Nuvessa.
The current CLINDESSE label states that its mineral-oil-containing vaginal cream may weaken latex or rubber condoms and contraceptive diaphragms. Those barriers should not be used during treatment or for five days after treatment; their reliability for pregnancy and STI prevention may be reduced during that interval. This is a specific CLINDESSE warning, not a rule for every vaginal antibiotic or for NUVESSA.
When barrier protection is needed, discuss alternatives and timing with the prescriber or pharmacist before the dose; do not assume the restriction ends when the single applicator is empty. The XACIATO gel warning instead concerns polyurethane condoms during and for seven days after treatment. Other clindamycin creams and ovules must be checked against their own instructions, not assigned an arbitrary common interval.
Clindesse labeling addresses prior hypersensitivity, certain bowel conditions and C. difficile-associated diarrhea. Metronidazole vaginal gel has its own adverse-effect and interaction profile. An individual with prior serious antibiotic reactions, unexplained bowel symptoms or pregnancy-related questions needs counseling before using either medicine.
Neither product is intended for fungal vaginitis, trichomoniasis or an unconfirmed symptom pattern. If symptoms resemble a yeast infection, a clinician may need testing rather than choosing between two antibiotics solely on the basis of a perceived odor or discharge.
CLINDESSE is labeled for bacterial vaginosis in non-pregnant women, while NUVESSA is labeled for BV in females 12 years of age and older; neither statement alone decides suitability in pregnancy or any other individual situation. CLINDESSE also has contraindications involving prior regional enteritis, ulcerative colitis or C. difficile-associated diarrhea. These are reasons to review the specific clinical history instead of basing a prescription choice on the convenience of one vaginal dose.
A FDA-approved 1.3% generic referencing Nuvessa has been documented, but that approval does not mean all pharmacies dispense it or that every prescription will permit a substitution. Clindesse brand status and any potential alternative need their own product-level verification. Brand familiarity alone is not proof of availability.
An accurate retail quote compares the single-dose packages actually prescribed, including network and prior-authorization rules. The Nuvessa cost page discusses one brand’s coverage factors without claiming Clindesse shares the same insurance terms.
Ask whether the exact medicine is Nuvessa 1.3% gel or Clindesse 2% cream, how many applicators are supplied and what warnings apply to vaginal products or barrier contraception. Confirm the order is valid and the package matches.
If the requested item is unavailable or the plan rejects the claim, contact the prescribing clinician for a decision. A replacement across these drugs should never occur silently during checkout. A treatment problem after use likewise calls for clinical reassessment rather than an unsupervised repeat dose.
Suppose a patient is prescribed Clindesse and plans to rely on latex condoms shortly after treatment. The pharmacist needs to explain the mineral-oil-related precautions from the Clindesse label, including the relevant interval. Simply asking whether an antibiotic is “vaginal” will not elicit the same information. Nuvessa has different ingredients and instructions; the prescriber may need to reconsider suitability based on the patient’s full situation.
That situation also differs from Xaciato, whose label specifically discusses polyurethane condoms. Readers should use the Nuvessa versus Xaciato comparison if they are evaluating two gels rather than a gel and cream. Borrowing an interval from a different clindamycin product could lead to incorrect counseling.
At the pharmacy, confirm whether a listing is for the one-dose Clindesse product or another clindamycin vaginal cream. Clindamycin cream access guidance explains how the requested form and product should be identified. The matching brand, package and applicator matter more than a broad claim that the products are used for BV.
Begin with the specific question answered on this page: Two brands with different active drugs but both single-dose vaginal preparations; comparison of routes and vehicles. Do not use a comparison page to diagnose an infection or choose an antibiotic without a licensed clinician. Identify the medical purpose of the current prescription and check that the intended medicine, dosage form and route are clear enough for the dispensing pharmacist to verify.
Before pickup, read the actual prescription for Nuvessa gel or Clindesse cream and confirm the applicator design and labeled brand package. Clindesse carries a mineral-oil-related barrier warning that requires product-specific counseling. If a cheaper product contains a different active antibiotic, an explicit clinician decision is necessary even if both products are designed for a single administration.
No. Nuvessa uses metronidazole, and Clindesse uses clindamycin.
Yes, these specific brand products have single-administration labeling, although their formulations are different.
No. Clindesse is a 2% vaginal cream.
Yes. CLINDESSE contains mineral oil that may weaken latex or rubber condoms and vaginal diaphragms. Its U.S. label advises against use of those barriers during treatment and for five days afterward; discuss protection options with a clinician or pharmacist.
No. They are different active drugs and require separate prescribing decisions.
An FDA-approved 1.3% vaginal metronidazole generic exists; actual pharmacy availability varies.
These are antibacterial BV medicines, not antifungal yeast treatments.
Yes. Side effects are product-specific, and unexpected or persistent symptoms deserve professional assessment.
No. Both require prescriptions.
Request prices for the exact one-time package and verify insurance conditions with the pharmacy.